Skip to main content
SpringerLink
Log in

General Aspects of Adverse Cutaneous Drug Reactions

  • Chapter
  • First Online:
Adverse Cutaneous Drug Reactions to Cardiovascular Drugs

Abstract

Adverse cutaneous drug reactions (ACDR) or drug eruptions represent one of the most common types of adverse reactions to drug therapy. The overall incidence rate is estimated around 2–3 % in hospitalized patients. Antibiotics, nonsteroidal antiinflammatory drugs (NSAIDs), and anticonvulsants are usually regarded as the most common inducers, but almost every drug may cause skin reactions. Advanced age, polypharmacy, and female gender are among the main factors predisposing to ACDR.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lee A, Thomson J. Drug-induced skin reactions. In: Adverse drug reactions. 2nd ed. London: Pharmaceutical Press; 2006. p. 125–56.

    Google Scholar 

  2. Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol. 2013;32:41–5. doi:10.3109/15569527.2012.702837.

    CAS  PubMed  Google Scholar 

  3. Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30:1011–30.

    CAS  PubMed  Google Scholar 

  4. Al-Niaimi F. Drug eruptions in dermatology. Expert Rev Dermatol. 2011;6:273–86.

    Google Scholar 

  5. Andersen WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol. 1995;131:468–73.

    CAS  PubMed  Google Scholar 

  6. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123–9.

    CAS  PubMed  Google Scholar 

  7. Haymore BR, Yoon J, Mikita CP, Klote MM, DeZee KJ. Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. Ann Allergy Asthma Immunol. 2008;101:495–9. doi:10.1016/S1081-1206(10)60288-8.

    PubMed  Google Scholar 

  8. Pichler WJ, Beeler A, Keller M, Lerch M, Posadas S, Schmid D, et al. Pharmacological interaction of drugs with immune receptors: the p-I concept. Allergol Int. 2006;55:17–25.

    CAS  PubMed  Google Scholar 

  9. Andersen KE, Hjorth N, Menné T. The baboon syndrome: systemically-induced allergic contact dermatitis. Contact Dermatitis. 1984;10:97–100.

    CAS  PubMed  Google Scholar 

  10. Özkaya E. Current understanding of Baboon syndrome. Exp Rev Dermatol. 2009;4:163–75.

    Google Scholar 

  11. Lerch M, Bircher AJ. Systemically induced allergic exanthem from mercury. Contact Dermatitis. 2004;50:349–53.

    CAS  PubMed  Google Scholar 

  12. Häusermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis. 2004;51:297–310.

    PubMed  Google Scholar 

  13. Summers EM, Bingham CS, Dahle KW, Sweeney C, Ying J, Sontheimer RD. Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers. JAMA Dermatol. 2013;149:814–8. doi:10.1001/jamadermatol.2013.511.

    PubMed  Google Scholar 

  14. Pfeiff B, Pullmann H. Baboon-artiges Arzneiexanthem auf heparin. Dermatologe. 1991;39:559–60.

    Google Scholar 

  15. Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol. 2011;11:313–8. doi:10.1097/ACI.0b013e3283489d5f.

    PubMed  Google Scholar 

  16. Almeida J, Levantine A. Lichenoid drugs eruptions. Br J Dermatol. 1971;85:604–7.

    Google Scholar 

  17. Woo V, Bonks J, Borukhova L, Zegarelli D. Oral lichenoid drug eruption: a report of a pediatric case and review of the literature. Pediatr Dermatol. 2009;26:458–64. doi:10.1111/j.1525-1470.2009.00953.x.

    PubMed  Google Scholar 

  18. Fessa C, Lim P, Kossard S, Richards S, Peñas PF. Lichen planus-like drug eruptions due to β-blockers: a case report and literature review. Am J Clin Dermatol. 2012;13:417–21. doi:10.2165/11634590-000000000-00000.

    PubMed  Google Scholar 

  19. Özkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges. 2008;6:181–8.

    PubMed  Google Scholar 

  20. Özkaya E. Oral mucosal fixed drug eruption: characteristics and differential diagnosis. J Am Acad Dermatol. 2013;69:e51–8. doi:10.1016/j.jaad.2012.08.019.

    PubMed  Google Scholar 

  21. Ahmed I, Reichenberg J, Lucas A, Shehan JM. Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review of the literature. Int J Dermatol. 2004;43:67–73.

    PubMed  Google Scholar 

  22. Wöhrl S, Loewe R, Pickl WF, Stingl G, Wagner SN. EMPACT syndrome. J Dtsch Dermatol Ges. 2005;3:39–43.

    PubMed  Google Scholar 

  23. Fabbrocini G, Panariello L, Pensabene M, Lauria R, Matano E, Martellotta D, et al. EMPACT syndrome associated with phenobarbital. Dermatitis. 2013;24:37–9. doi:10.1097/DER.0b013e31827ede32.

    CAS  PubMed  Google Scholar 

  24. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28:1133–40. doi:10.1111/jdv.12366.

  25. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol. 2011;29:455–7. doi:10.1016/j.clindermatol.2011.01.016.

    PubMed  Google Scholar 

  26. Ramsay CA. Drug induced pseudoporphyria. J Rheumatol. 1991;18:799–800.

    CAS  PubMed  Google Scholar 

  27. Maruani A, Machet MC, Carlotti A, Giraudeau B, Vaillant L, Machet L. Immunostaining with antibodies to desmoglein provides the diagnosis of drug-induced pemphigus and allows prediction of outcome. Am J Clin Pathol. 2008;130:369–74.

    PubMed  Google Scholar 

  28. Chanal J, Ingen-Housz-Oro S, Ortonne N, Duong TA, Thomas M, Valeyrie-Allanore L, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol. 2013;169:1041–8. doi:10.1111/bjd.12488.

    CAS  PubMed  Google Scholar 

  29. Newby CS, Barr RM, Greaves MW, Mallet AI. Cytokine release and cytotoxicity in human keratinocytes and fibroblasts induce d by phenols and sodium dodecyl sulfate. J Invest Dermatol. 2000;115:292–8.

    CAS  PubMed  Google Scholar 

  30. Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G, et al. In vitro and in vivo expression of interleukin-1α and tumor necrosis factor-α mRNA in pemphigus vulgaris: interleukin-1α and tumor necrosis factor-α are involved in acantholysis. J Invest Dermatol. 2000;114:71–7.

    CAS  PubMed  Google Scholar 

  31. Ruocco V, De Angelis E, Lombardi ML. Drug-induced pemphigus. II. Pathomechanisms and experimental investigations. Clin Dermatol. 1993;11:507–13.

    CAS  PubMed  Google Scholar 

  32. Fernando SL. Acute generalised exanthematous pustulosis. Australas J Dermatol. 2012;53:87–92. doi:10.1111/j.1440-0960.2011.00845.x.

    PubMed  Google Scholar 

  33. Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127:1333–8.

    CAS  PubMed  Google Scholar 

  34. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern. J Cutan Pathol. 2001;28:113–9.

    CAS  PubMed  Google Scholar 

  35. Momin SB, Peterson A, Del Rosso JQ. A status report on drug-associated acne and acneiform eruptions. J Drugs Dermatol. 2010;9:627–36.

    PubMed  Google Scholar 

  36. Scheinfeld NS, Chernoff K, Derek Ho MK, Liu YC. Drug-induced photoallergic and phototoxic reactions – an update. Expert Opin Drug Saf. 2014;13:321–40. doi:10.1517/14740338.2014.885948.

    CAS  PubMed  Google Scholar 

  37. Badri T, Ben Tekaya N, Cherif F, Ben Osman Dhahri A. Photo-onycholysis: two cases induced by doxycycline. Acta Dermatovenerol Alp Panonica Adriat. 2004;13:135–6.

    CAS  Google Scholar 

  38. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011;34:821–37. doi:10.2165/11592780-000000000-00000.

    CAS  PubMed  Google Scholar 

  39. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2:253–62.

    CAS  PubMed  Google Scholar 

  40. Conroy EA, Liranzo MO, McMahon J, Steck WD, Tuthill RJ. Quinidine-induced pigmentation. Cutis. 1996;57:425–7.

    CAS  PubMed  Google Scholar 

  41. Gonzalez-Arriagada WA, Silva AR, Vargas PA, de Almeida OP, Lopes MA. Facial pigmentation associated with amiodarone. Gen Dent. 2013;61:e15–7.

    PubMed  Google Scholar 

  42. Cox NH, Walsh ML, Robson RH. Purpura and bleeding due to calcium-channel blockers: an underestimated problem? Case reports and a pilot study. Clin Exp Dermatol. 2009;34:487–91. doi:10.1111/j.1365-2230.2008.03048.x.

    CAS  PubMed  Google Scholar 

  43. Dootson G, Byatt C. Amiodarone-induced vasculitis and a review of the cutaneous side-effects of amiodarone. Clin Exp Dermatol. 1994;19:422–4.

    CAS  PubMed  Google Scholar 

  44. Veloso HH, De Paola AA. Thrombophlebitis: a common complication of amiodarone. Am Fam Physician. 2004;70:1448.

    PubMed  Google Scholar 

  45. Al-Niaimi F, Lyon C. Felodipine-induced eruptive telangiectasia following mastectomy and radiotherapy. Br J Dermatol. 2010;162:210–1. doi:10.1111/j.1365-2133.2009.09497.x.

    CAS  PubMed  Google Scholar 

  46. Pendergraft WF, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014;26:42–9. doi:10.1097/BOR.0000000000000014.

    CAS  PubMed  Google Scholar 

  47. Papagrigoraki A, Gisondi P, Rosina P, Cannone M, Girolomoni G. Erythema nodosum: etiological factors and relapses in a retrospective cohort study. Eur J Dermatol. 2010;20:773–7. doi:10.1684/ejd.2010.1116.

    PubMed  Google Scholar 

  48. Sharma G, Govil DC. Allopurinol induced erythroderma. Indian J Pharmacol. 2013;45:627–8. doi:10.4103/0253-7613.121381.

    PubMed Central  PubMed  Google Scholar 

  49. Finkelstein Y, Soon GS, Acuna P, George M, Pope E, Ito S, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128:723–8. doi:10.1542/peds.2010-3322.

    PubMed  Google Scholar 

  50. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol. 2007;56:181–200.

    PubMed  Google Scholar 

  51. Castelain F, Humbert P. Toxic epidermal necrolysis. Curr Drug Saf. 2012;7:332–8.

    CAS  PubMed  Google Scholar 

  52. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53.

    CAS  PubMed  Google Scholar 

  53. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69:187.e1–16. doi:10.1016/j.jaad.2013.05.002; quiz 203–4.

    CAS  Google Scholar 

  54. Verma R, Vasudevan B, Pragasam V. Severe cutaneous adverse drug reactions. Med J Armed Forces India. 2013;69:375–83.

    PubMed Central  PubMed  Google Scholar 

  55. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323–7.

    CAS  PubMed  Google Scholar 

  56. Ständer S, Metze D, Luger T, Schwarz T. Drug reaction with eosinophilia and systemic symptoms (DRESS): a review. Hautarzt. 2013;64:611–22. doi:10.1007/s00105-013-2615-0; quiz 623–4.

    PubMed  Google Scholar 

  57. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156:609–11.

    CAS  PubMed  Google Scholar 

  58. Yazganoglu KD, Özkaya E, Ergin-Özcan P, Çakar N. Vancomycin-induced drug hypersensitivity syndrome. J Eur Acad Dermatol Venereol. 2005;19:648–50.

    CAS  PubMed  Google Scholar 

  59. Choi TS, Doh KS, Kim SH, Jang MS, Suh KS, Kim ST. Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br J Dermatol. 2003;148:730–6.

    CAS  PubMed  Google Scholar 

  60. Mutasim DF. Lymphomatoid drug eruption mimicking digitate dermatosis: cross reactivity between two drugs that suppress angiotensin II function. Am J Dermatopathol. 2003;25:331–4.

    PubMed  Google Scholar 

  61. Pulitzer MP, Nolan KA, Oshman RG, Phelps RG. CD30+ lymphomatoid drug reactions. Am J Dermatopathol. 2013;35:343–50. doi:10.1097/DAD.0b013e31826bc1e5.

    PubMed  Google Scholar 

  62. Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61:325–32. doi:10.1016/j.jaad.2008.12.039.

    PubMed  Google Scholar 

  63. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev. 2010;10:46–50. doi:10.1016/j.autrev.2010.07.005.

    CAS  PubMed  Google Scholar 

  64. Levine D, Switlyk SA, Gottlieb A. Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature. J Drugs Dermatol. 2010;9:1283–7.

    PubMed  Google Scholar 

  65. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009;18:935–40. doi:10.1177/0961203309106176.

    CAS  PubMed  Google Scholar 

  66. Callen JP. Drug-induced subacute cutaneous lupus erythematosus. Lupus. 2010;19:1107–11. doi:10.1177/0961203310370349.

    CAS  PubMed  Google Scholar 

  67. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009;301:65–70. doi:10.1007/s00403-008-0890-x.

    PubMed  Google Scholar 

  68. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139:45–9.

    CAS  PubMed  Google Scholar 

  69. Bulut M, Yazganoglu KD, Buyukbabani N, Özkaya E. Subacute cutaneous lupus erythematosus-like eruption possibly induced by filgrastim, a granulocyte colony-stimulating factor. EADV 22nd Congress, İstanbul, 2–6 October 2013, Programme book. p. 152 (P 109).

    Google Scholar 

  70. Milavec-Puretić V, Mance M, Ceović R, Lipozenčić J. Drug induced psoriasis. Acta Dermatovenerol Croat. 2011;19:39–42.

    PubMed  Google Scholar 

  71. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol. 2000;1:159–65.

    CAS  PubMed  Google Scholar 

  72. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol. 1999;455:221–5.

    CAS  PubMed  Google Scholar 

  73. Yerushalmi J, Zvulunov A, Halevy S. Serum sickness-like reactions. Cutis. 2002;69:395–7.

    PubMed  Google Scholar 

  74. Ständer S, Darsow U, Mettang T, Gieler U, Maurer M, Ständer H, et al. S2k guideline–Chronic Pruritus. J Dtsch Dermatol Ges. 2012;10 Suppl 4:S1–27. doi:10.1111/j.1610-0387.2012.08005.x.

    PubMed  Google Scholar 

  75. Claeys A, Weber-Muller F, Trechot P, Cuny JF, Georges MY, Barbaud A, et al. Cutaneous, perivulvar and perianal ulcerations induced by nicorandil. Br J Dermatol. 2006;155:494–6.

    CAS  PubMed  Google Scholar 

  76. Ghersetich I, Rindi L, Teofoli P, Tsampau D, Palleschi GM, Lotti T. Pityriasis rosea-like skin eruptions caused by captopril. G Ital Dermatol Venereol. 1990;125:457–9.

    CAS  PubMed  Google Scholar 

  77. Sugita K, Kabashima K, Nakamura M, Tokura Y. Drug-induced papuloerythroderma: analysis of T-cell populations and a literature review. Acta Derm Venereol. 2009;89:618–22.

    PubMed  Google Scholar 

  78. Sugita K, Kabashima K, Nakashima D, Tokura Y. Papuloerythroderma of Ofuji induced by furosemide. J Am Acad Dermatol. 2008;58(2 Suppl):S54–5. doi:10.1016/j.jaad.2006.05.046.

    PubMed  Google Scholar 

  79. Sugita K, Koga C, Yoshiki R, Izu K, Tokura Y. Papuloerythroderma caused by aspirin. Arch Dermatol. 2006;142:792–3.

    PubMed  Google Scholar 

  80. Thompson DF, Montarella KE. Drug-induced Sweet’s syndrome. Ann Pharmacother. 2007;41:802–11.

    CAS  PubMed  Google Scholar 

  81. Roujeau JC. Neutrophilic drug eruptions. Clin Dermatol. 2000;18:331–7.

    CAS  PubMed  Google Scholar 

  82. Bremner R, Simpson E, White CR, Morrison L, Deodhar A. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. Semin Arthritis Rheum. 2004;34:610–6.

    PubMed  Google Scholar 

  83. Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25:72–8.

    CAS  PubMed  Google Scholar 

  84. Magro CM, Cruz-Inigo AE, Votava H, Jacobs M, Wolfe D, Crowson AN. Drug-associated reversible granulomatous T cell dyscrasia: a distinct subset of the interstitial granulomatous drug reaction. J Cutan Pathol. 2010;37 Suppl 1:96–111.

    PubMed  Google Scholar 

  85. Perrin C, Lacour JP, Castanet J, Michiels JF. Interstitial granulomatous drug reaction with a histological pattern of interstitial granulomatous dermatitis. Am J Dermatopathol. 2001;23:295–8.

    CAS  PubMed  Google Scholar 

  86. Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK. Interstitial and granulomatous drug reaction presenting as erythema nodosum-like lesions. Acta Derm Venereol. 2002;82:473–4.

    CAS  PubMed  Google Scholar 

  87. Yazganoğlu KD, Tambay E, Mete Ö, Özkaya E. Interstitial granulomatous drug reaction due to thalidomide. J Eur Acad Dermatol Venereol. 2009;23:490–3. doi:10.1111/j.1468-3083.2008.02953.x.

    PubMed  Google Scholar 

  88. Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis: incidence, prevention and management. Drug Saf. 2008;31:109–26.

    CAS  PubMed  Google Scholar 

  89. Torpet LA, Kragelund C, Reibel J, Nauntofte B. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med. 2004;15:28–46.

    PubMed  Google Scholar 

  90. Habbab KM, Moles DR, Porter SR. Potential oral manifestations of cardiovascular drugs. Oral Dis. 2010;16:769–73. doi:10.1111/j.1601-0825.2010.01686.x.

    CAS  PubMed  Google Scholar 

  91. Pillans PI, Woods DJ. Drug-associated alopecia. Int J Dermatol. 1995;34:149–58.

    CAS  PubMed  Google Scholar 

  92. Piraccini BM, Iorizzo M, Rech G, Tosti A. Drug-induced hair disorders. Curr Drug Saf. 2006;1:301–5.

    CAS  PubMed  Google Scholar 

  93. Piraccini BM, Alessandrini A. Drug-related nail disease. Clin Dermatol. 2013;31:618–26. doi:10.1016/j.clindermatol.2013.06.013.

    PubMed  Google Scholar 

  94. Kynaston HG, Roberts DH, Davies WT. Peripheral gangrene associated with beta-blockade. Br J Surg. 1987;74:760.

    CAS  PubMed  Google Scholar 

  95. Coombs PR, Gell PG. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell RR, editor. Clinical aspects of immunology. Oxford: Oxford University Press; 1968. p. 575–96.

    Google Scholar 

  96. Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol. 2010;10:291–6. doi:10.1097/ACI.0b013e32833aa54d.

    CAS  PubMed  Google Scholar 

  97. Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions – new concepts. Clin Exp Allergy. 2007;37:989–99.

    CAS  PubMed  Google Scholar 

  98. Yawalkar N, Pichler WJ. Mechanisms of cutaneous drug reactions. J Dtsch Dermatol Ges. 2004;2:1013–23.

    PubMed  Google Scholar 

  99. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139:683–93.

    CAS  PubMed  Google Scholar 

  100. Lee HY, Chung WH. Toxic epidermal necrolysis: the year in review. Curr Opin Allergy Clin Immunol. 2013;13:330–6. doi:10.1097/ACI.0b013e3283630cc2.

    CAS  PubMed  Google Scholar 

  101. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343–50. doi:10.1038/nm.1884.

    CAS  PubMed  Google Scholar 

  102. Özkaya E, Babuna G. A challenging case: symmetrical drug related intertriginous and flexural exanthem, fixed drug eruption, or both? Pediatr Dermatol. 2011;28:711–4. doi:10.1111/j.1525-1470.2011.01656.x.

    PubMed  Google Scholar 

  103. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol. 2000;164:6647–54.

    CAS  PubMed  Google Scholar 

  104. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–32.

    CAS  PubMed  Google Scholar 

  105. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.

    CAS  PubMed  Google Scholar 

  106. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  107. Pellicano R, Ciavarella G, Lomuto M, Di Giorgio G. Genetic susceptibility to fixed drug eruptions: evidence for a link with HLA-B22. J Am Acad Dermatol. 1994;30:52–4.

    CAS  PubMed  Google Scholar 

  108. Pellicano R, Lomuto M, Ciavarella G, Di Giorgio G, Gasparini P. Fixed drug eruptions with feprazone are linked to HLA-B22. J Am Acad Dermatol. 1997;36:782–4.

    CAS  PubMed  Google Scholar 

  109. Ozkaya E, Akar U. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol. 2001;45:712–7.

    Google Scholar 

  110. Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450 s. J Am Acad Dermatol. 2002;47:467–84.

    PubMed  Google Scholar 

  111. Gex-Collet C, Helbling A, Pichler WJ. Multiple drug hypersensitivity-proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests. J Investig Allergol Clin Immunol. 2005;15:293–6.

    CAS  PubMed  Google Scholar 

  112. Asero R. Multiple drug allergy syndrome: a distinct clinical entity. Curr Allergy Rep. 2001;1:18–22.

    CAS  PubMed  Google Scholar 

  113. Halevy S, Grossman N. Multiple drug allergy in patients with cutaneous adverse drug reactions diagnosed by in vitro drug-induced interferon-gamma release. Isr Med Assoc J. 2008;10:865–8.

    PubMed  Google Scholar 

  114. Voltolini S, Bignardi D, Minale P, Pellegrini S, Troise C. Phenobarbital- induced DiHS and ceftriaxone hypersensitivity reaction: a case of multiple drug allergy. Eur Ann Allergy Clin Immunol. 2009;41:62–3.

    CAS  PubMed  Google Scholar 

  115. Özkaya E. Eczematous type multiple drug allergy from isoniazid and ethambutol with positive patch test results. Cutis. 2013;92:121–4.

    PubMed  Google Scholar 

  116. Özkaya E, Yazganoglu KD. Sequential development of eczematous type “multiple drug allergy” to unrelated drugs. J Am Acad Dermatol. 2011;65:e26–9. doi:10.1016/j.jaad.2010.12.028.

    PubMed  Google Scholar 

  117. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.

    CAS  PubMed  Google Scholar 

  118. Moore N, Biour M, Paux G, Loupi E, Begaud B, Boismare F, et al. Adverse drug reaction monitoring: doing it the French way. Lancet. 1985;2(8463):1056–8.

    CAS  PubMed  Google Scholar 

  119. The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. http://who-umc.org/Graphics/24734.pdf. Accessed 31 Mar 2014.

  120. Seitz CS, Rose C, Kerstan A, Trautmann A. Drug-induced exanthems: correlation of allergy testing with histologic diagnosis. J Am Acad Dermatol. 2013;69:721–8. doi:10.1016/j.jaad.2013.06.022.

    CAS  PubMed  Google Scholar 

  121. Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998;139:49–58.

    CAS  PubMed  Google Scholar 

  122. Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol. 2007;7:299–303.

    PubMed  Google Scholar 

  123. Sanz ML, García BE, Prieto I, Tabar A, Oehling A. Specific IgE determination in the diagnosis of beta-lactam allergy. J Investig Allergol Clin Immunol. 1996;6:89–93.

    CAS  PubMed  Google Scholar 

  124. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59:809–20.

    CAS  PubMed  Google Scholar 

  125. Goossens C, Sass U, Song M. Baboon syndrome. Dermatology. 1997;194:421–2.

    CAS  PubMed  Google Scholar 

  126. Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler C, et al. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests. J Allergy Clin Immunol. 2005;115:179–85.

    CAS  PubMed  Google Scholar 

  127. Halevy S, Cohen AD, Grossman N. Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions. J Am Acad Dermatol. 2005;52:254–61.

    PubMed  Google Scholar 

  128. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58:854–63.

    CAS  PubMed  Google Scholar 

  129. Mahajan VK, Handa S. Patch testing in cutaneous adverse drug reactions: methodology, interpretation, and clinical relevance. Indian J Dermatol Venereol Leprol. 2013;79:836–41. doi:10.4103/0378-6323.120751.

    PubMed  Google Scholar 

  130. Ozkaya E, Bayazit H, Ozarmagan G. Drug related clinical pattern in fixed drug eruption. Eur J Dermatol. 2000;10:288–91.

    Google Scholar 

  131. Méndez J, Sanchís ME, de la Fuente R, Stolle R, Vega JM, Martínez C, et al. Delayed-type hypersensitivity to subcutaneous enoxaparin. Allergy. 1998;53:999–1003.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Venereology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

    Esen Özkaya & Kurtuluş Didem Yazganoğlu

Authors
  1. Esen Özkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kurtuluş Didem Yazganoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Özkaya, E., Yazganoğlu, K.D. (2014). General Aspects of Adverse Cutaneous Drug Reactions. In: Adverse Cutaneous Drug Reactions to Cardiovascular Drugs. Springer, London. https://doi.org/10.1007/978-1-4471-6536-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6536-1_1

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6535-4

  • Online ISBN: 978-1-4471-6536-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation